Deals and Wins

Foley Represents TCGX in $30M Private Placement Financing in Nektar Therapeutics

Foley & Lardner LLP represented TCG Crossover (“TCGX”) in the $30 million private placement financing in Nektar Therapeutics, a biotechnology company developing medicines for the treatment of auto-immune disorders.

Nektar Therapeutics is a biotechnology company with a wholly owned R&D pipeline of investigational medicines in immunology and oncology as well as a portfolio of approved partnered medicines. This financing will further bolster the company’s financial position and extend its cash runway well into the third quarter of 2026.

TCGX supports private and public companies building the future of medicine. As a Palo Alto-based investment firm focused on investing in innovative pre-IPO and public drug discovery companies, TCGX invests in visionary entrepreneurs leveraging recent scientific breakthroughs to develop transformative medicines.

The Foley team was led by partners Louis Lehot and Clyde Tinnen with support from associate Trevor Mullin.